DMAA. Dendrobium. Aegeline. Utter the words in a room full of supplement industry executives, and you’ll likely hear a collective groan.
In the past year, these controversial stimulants have been subject to everything from recalls and seizures to class action suits, scathing media exposÃ©s, and threats of criminal prosecution. They prompted lawmakers to call for more strict regulation of supplements, and
All access premium subscription
This content requires a subscription to Nutrition Business Journal.
As an NBJ subscriber, you receive 10 issues a year and access to the exclusive “NBJ subscriber only” content on newhope.com (excludes three-month subscriptions), which includes PowerPoint presentations, select data charts and archived articles. Subscribers also receive a 10 percent discount on data charts, comprehensive market research reports and webinars.
Email [email protected] for more information about subscribing.